首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2126426

神經退化性疾病生物標記市場－策略分析與預測（2026-2035）

Neurodegenerative Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計神經退化性疾病生物標記的市場規模將從 2026 年的 48.1 億美元成長到 2035 年的 126.8 億美元，複合年成長率為 11.4%。

神經退化性疾病標記市場正經歷顯著的變革，其驅動力來自疾病早期檢測的模式轉移以及疾病修正治療的出現。這一市場演變的特點是，人們日益認知到客觀的生物學指標對於在神經功能顯著下降之前識別神經退化性疾病至關重要，從而能夠及時治療性介入。免疫檢測、分子診斷和神經影像技術等先進分析平台的融合，使得生物標記的檢測更加靈敏、特異和便利。由於治療效果越來越依賴臨床前和早期症狀發作時的干預，醫療保健系統需要客觀的方法來更早地識別阿茲海默症、帕金森氏症和肌萎縮側索硬化症（ALS）等疾病。疾病修正治療的出現持續影響對生物標記的需求，因為治療的成功取決於疾病狀態的生物學確認和患者分層。隨著生物學證據不斷改善臨床試驗設計和治療評估，監管機構也日益認知到生物標記是神經系統藥物研發中不可或缺的工具。隨著對基於血液的生物標記技術、多體學方法和人工智慧驅動的分析平台的大量投資，神經退化性疾病生物標記正在成為全球醫療保健系統中精準神經病學的關鍵組成部分。

市場促進因素

對早期疾病檢測日益成長的需求是神經退化性疾病生物標記市場的主要驅動力。早期發現疾病能夠提高治療性介入和長期疾病管理的時機。隨著臨床醫生尋求在出現顯著神經功能衰退之前識別疾病狀態的方法，對神經退化性疾病生物標記的需求不斷成長。這項需求促使診斷技術開發商提高生物標記的靈敏度和可近性。各公司正在擴展血液檢測和分子診斷技術以支持早期診斷。因此，主導生物標記的診斷策略的應用日益廣泛，神經退化性疾病生物標記的應用也在穩步成長。此外，疾病修正治療的擴展也增加了對患者識別和治療監測的需求，進一步加速了市場成長。疾病修正治療依賴準確的患者識別和治療監測。由於治療效果越來越依賴疾病狀態的生物學確認，對檢驗的生物標記的需求也在成長。這種依賴性限制了基於症狀的診斷方法在患者選擇中的效用。製藥公司正在將生物標記整合到其臨床開發項目中，以改善治療評估。因此，生物標記的應用正在整體治療決策流程中不斷擴展。基於血液的生物標記技術的進步正在提高其可及性和擴充性。血液檢測正成為侵入性診斷程序的更便捷替代方案。隨著醫療專業人員尋求可擴展的解決方案以惠及更多患者，對血液來源生物標記的需求也在不斷成長。這種轉變正在挑戰人們對傳統腦脊髓液檢測和先進影像技術的依賴。診斷公司正致力於改善檢測效能和檢驗標準，以提高臨床可靠性。因此，基於血液的生物標記檢測的應用正在增加。在臨床試驗中不斷擴大的應用正在推動生物標記在神經系統藥物研發中的整合。臨床試驗的成功越來越依賴於準確識別疾病的生物學特徵和進展。隨著申辦者尋求客觀指標來支持患者選擇和終點評估，對神經退化性疾病生物標記的需求也不斷成長。

市場限制因素

神經退化性疾病通常進展緩慢，需要長期療效評估，這使得臨床檢驗仍然十分複雜。這些疾病的緩慢進展為生物標記的效用驗證帶來了挑戰。由於不同檢查室和分析平台的生物標記檢測調查方法存在差異，標準化仍然是一個難題。缺乏統一的方案降低了可比性和臨床可靠性。由於醫療系統仍在評估新型生物標記技術的臨床和經濟價值，保險報銷的不確定性限制了其應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。複雜的司法管轄區法規也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對技術和生物標記類型的深入了解

技術發展趨勢的特徵是整合診斷平台和多體學方法的重要性日益凸顯。隨著醫療服務提供者尋求可靠且臨床上易於獲取的檢測方法，對免疫檢測和分子診斷的需求不斷成長。這項需求凸顯了高度專業化的診斷方法的局限性，這些方法仍然難以規模化應用。次世代定序(NGS) 在基因組和轉錄組生物標記的發現方面正被廣泛應用。質譜分析在全面的蛋白質體學分析中也得到了越來越廣泛的應用。神經影像技術持續為大腦的結構和功能評估提供支援。隨著片段分析擴大用於檢測病理蛋白（例如乙型澱粉樣蛋白、磷酸化Tau和神經絲輕鏈）以早期發現疾病，人們對蛋白質生物標記的需求正在轉向蛋白質生物標記。遺傳生物標記能夠揭示遺傳風險和疾病易感性。影像生物標記能夠可視化大腦的結構和功能變化。代謝和發炎生物標記提供了更豐富的生物學背景資訊。阿茲海默症是應用最廣泛的領域。這是因為治療創新越來越依賴疾病狀態的生物學確認。帕金森氏症、肌萎縮側索硬化症（ALS）、亨丁頓舞蹈症和多重系統退化症症是重要且快速成長的應用領域。隨著醫療專業人員尋求創傷性較小的診斷方案，血液樣本已成為成長最快的檢體類型。腦脊髓液在需要更高靈敏度的特定應用中仍然發揮著至關重要的作用。製藥和生物技術公司是主要的終端用戶群體，生物標記在診斷實驗室和學術研究機構中的應用正在不斷擴展。隨著生物標記研究產生龐大而複雜的資料集，人工智慧的整合變得日益重要。行業相關人員正在採用機器學習技術來提高診斷準確性和預測性能。

競爭格局與策略展望

競爭格局包括成熟的診斷和製藥公司，以及專注於生物標記、神經病學和分析技術的供應商。羅氏憑藉其製藥專長和醫療保健行業最全面的診斷產品組合之一，以及不斷擴展的生物標記解決方案（旨在支持神經系統疾病診療路徑中的診斷、患者分層和治療監測），保持著獨特的戰略地位。 Fujiri Bio憑藉其在神經退化性疾病生物標記開發（尤其是阿茲海默症診斷）方面積累的豐富經驗，佔據領先地位，並正加大在檢測方法開發和檢驗的投入，以提高臨床應用和可及性。 Quantelix憑藉其超主導的生物標記檢測技術脫穎而出，該技術能夠識別低濃度的生物訊號，從而擴展了其Simoa平台在阿茲海默症、帕金森氏症、肌萎縮側索硬化症（ALS）及相關神經系統疾病中的應用範圍。隨著神經退化性疾病生物標記的開發越來越依賴先進的分子分析和定量測量技術，Bio-Rad 保持其戰略重要性，並正在擴展其分子診斷和生命科學研究能力，以支持生物標記的發現和檢驗舉措。 Thermo Fisher Scientific 憑藉其廣泛的技術支援生物標記的發現、檢驗和商業化，佔據著重要的市場地位，並正在擴展其分析技術和實驗室解決方案，以滿足不斷變化的需求。 QIAGEN 憑藉其在分子診斷、樣本製備技術和生物標記開發支援方面的專業知識保持著競爭力，並正在擴展其技術以支持生物標記的發現、轉化研究和臨床應用活動。 Siemens HealthInars 則憑藉其在影像和臨床實驗室診斷方面的專業知識脫穎而出，這些技術在神經退化性疾病的管理中發揮著至關重要的作用。每家公司都在透過在血液衍生生物標記檢測、多體學平台和人工智慧驅動的解讀工具方面的創新來推動產品系列的擴展。在生物標記發現和檢驗需求的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。地理擴張仍然是一項關鍵戰略重點，各公司將目光投向了快速成長的亞太地區和新興市場，這些地區由於人口老齡化，神經退化性疾病的負擔日益加重。

簡明結論

神經退化性疾病標記市場預計將持續成長，這主要得益於早期疾病檢測、疾病修正治療和技術創新三者的融合發展。從以研究為主導的工具轉向神經健康照護的基礎要素，標誌著疾病管理方式的根本性變革。儘管在臨床檢驗、標準化和保險報銷方面仍存在挑戰，但對技術、夥伴關係和證據產生的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景依然樂觀，神經退化性疾病生物標記有望發展成為精準神經病學的關鍵組成部分，在全球醫療保健系統中支持早期診斷、治療方案選擇、治療進展監測和藥物研發。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

市場定義和範圍
神經退化性疾病概述
產業變化
主要市場趨勢
實際成果值市場規模分析
市場預測分析
疾病負擔與臨床未滿足需求分析
發病率和盛行率分析
已確診患者族群的分析
對所進行的生物標記檢測數量進行分析
神經退化性疾病的診斷路徑分析
生物標記在疾病早期檢測中的作用
生物標記在治療監測中的作用

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態
相關人員生態系統分析
臨床實驗室和診斷基礎設施分析

第6章：創新趨勢

神經退化性疾病生物標記的新興技術
產品創新趨勢
臨床試驗分析
神經退化性疾病生物標記的管道分析
血液來源生物標記的發展趨勢
多組體學物標誌物的創新
人工智慧在生物標記發現與解讀的應用
數位生物標記的發展趨勢
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求
生物標記合格評估計劃
診斷有效性要求

第8章：神經退化性疾病生物標記市場：展望分析

分析：依生物標記類型
分析：按技術平台
分析：依檢體類型
分析：根據指示
分析：透過臨床應用
分析：透過測試方法
分析：按最終用戶
分析：按發展階段

第9章：神經退化性疾病生物標記市場：細分市場分析

依生物標誌類型
- 蛋白質生物標記
- 基因生物標記
- 影像生物標記
- 代謝生物標記
- 發炎生物標記
適應症
- 阿茲海默症
- 帕金森氏症
- 肌萎縮側索硬化症（ALS）
- 亨丁頓舞蹈症
- 多重系統退化症
- 其他神經退化性疾病
透過技術平台
- 免疫測量
- 分子診斷
- 次世代定序（NGS）
- 質譜分析
- 神經影像技術
依檢體類型
- 血
- 腦脊髓液（CSF）
- 組織樣本
- 其他生物檢體
最終用戶
- 醫院和診所
- 診斷檢查室
- 學術研究機構
- 製藥和生物技術公司
- CRO（委外研發機構）

第10章：神經退化性疾病生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：神經退化性疾病生物標記市場：國家分析

美國
加拿大
德國
英國
法國
瑞典
日本
中國
韓國
澳洲
印度
西班牙

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布
競爭基準
生物標記開發夥伴關係分析

第13章：公司簡介

F. Hoffmann-La Roche Ltd
Fujirebio Holdings, Inc.
Quanterix Corporation
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
QIAGEN NV
Danaher Corporation
Siemens Healthineers AG
Revvity, Inc.
C2N Diagnostics, LLC
Eisai Co., Ltd.
Biogen Inc.
Agilent Technologies, Inc.
Alamar Biosciences, Inc.
Sysmex Corporation

第14章：神經退化性疾病生物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資
神經科學研究的資金籌措狀況
精準神經學領域的投資趨勢
生物標誌研發經費資金籌措

第16章：未來展望

主要成長機遇
未來產業趨勢
神經退化性疾病血液衍生生物標記的研究進展
利用人工智慧發現生物標記的前景
疾病早期檢測與監測的未來
長期市場展望（2035 年）

簡介目錄

Product Code: KSI-009079

The Neurodegenerative Biomarkers Market is anticipated to grow at a CAGR of 11.4% from USD 4.81 billion in 2026 to USD 12.68 billion in 2035.

The neurodegenerative biomarkers market is undergoing significant transformation driven by the paradigm shift toward early disease detection and the emergence of disease-modifying therapies. The market's evolution is characterized by the growing recognition that objective biological indicators are essential for identifying neurodegenerative diseases before significant neurological decline occurs, enabling timely therapeutic intervention. The convergence of advanced analytical platforms, including immunoassays, molecular diagnostics, and neuroimaging technologies, is enabling more sensitive, specific, and accessible biomarker detection. Healthcare systems are seeking objective methods for identifying diseases such as Alzheimer's, Parkinson's, and ALS at earlier stages, as treatment effectiveness increasingly depends on intervention during preclinical or early symptomatic phases. The emergence of disease-modifying therapies continues influencing biomarker demand because treatment success relies on biological confirmation of disease status and patient stratification. Regulatory agencies increasingly recognize biomarkers as essential tools for neurological drug development, as biological evidence improves trial design and treatment evaluation. The market is witnessing significant investment in blood-based biomarker technologies, multi-omics approaches, and AI-enabled interpretation platforms, positioning neurodegenerative biomarkers as a critical component of precision neurology across global healthcare systems.

Market Drivers

The increasing demand for early disease detection represents the primary driver for the neurodegenerative biomarkers market. Early disease detection improves opportunities for therapeutic intervention and long-term disease management. Demand for neurodegenerative biomarkers is increasing because clinicians seek methods capable of identifying pathology before significant neurological decline occurs. This requirement creates pressure on diagnostic developers to improve biomarker sensitivity and accessibility. Companies are expanding blood-based and molecular diagnostic technologies to support earlier diagnosis. The outcome is stronger adoption of biomarker-driven diagnostic strategies, resulting in sustained growth in neurodegenerative biomarker utilization. The expansion of disease-modifying therapies is further accelerating market growth through demand for patient identification and treatment monitoring. Disease-modifying therapies depend on accurate patient identification and treatment monitoring. Demand for validated biomarkers is rising because therapeutic effectiveness increasingly relies on biological confirmation of disease status. This dependency limits the usefulness of symptom-based diagnostic approaches for patient selection. Pharmaceutical developers are integrating biomarkers throughout clinical development programs to improve treatment evaluation. The result is greater utilization of biomarkers across therapeutic decision-making processes. Advancements in blood-based biomarker technologies are expanding accessibility and scalability. Blood-based testing provides a more accessible alternative to invasive diagnostic procedures. Demand for blood-derived biomarkers is increasing because healthcare providers seek scalable solutions that support broader patient access. This shift challenges traditional reliance on cerebrospinal fluid testing and advanced imaging modalities. Diagnostic companies are improving assay performance and validation standards to enhance clinical confidence. The outcome is growing adoption of blood-based biomarker testing. Increasing utilization in clinical trials is driving expansion of biomarker integration throughout neurological drug development. Clinical trial success increasingly depends on accurate identification of disease biology and progression. Demand for neurodegenerative biomarkers is rising because sponsors require objective measures capable of supporting patient selection and endpoint evaluation.

Market Restraints

Clinical validation remains complex because neurodegenerative diseases often progress over extended periods and require long-term outcome assessment. The slow progression of these diseases creates challenges for demonstrating biomarker utility. Standardization challenges persist because biomarker testing methodologies vary across laboratories and analytical platforms. The lack of harmonized protocols reduces comparability and clinical confidence. Reimbursement uncertainty limits adoption because healthcare systems continue evaluating the clinical and economic value of emerging biomarker technologies. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of integrated diagnostic platforms and multi-omics approaches. Demand for immunoassays and molecular diagnostics is increasing because healthcare providers seek reliable and clinically accessible testing methods. This requirement exposes limitations associated with highly specialized diagnostic approaches that remain difficult to scale. NGS is expanding for genomic and transcriptomic biomarker discovery. Mass spectrometry is gaining adoption for comprehensive proteomic profiling. Neuroimaging technologies continue supporting structural and functional brain assessment. The segment analysis reveals that demand is shifting toward protein biomarkers because pathological proteins such as amyloid beta, phosphorylated tau, and neurofilament light chain increasingly support earlier disease identification. Genetic biomarkers provide insight into hereditary risk and disease susceptibility. Imaging biomarkers enable visualization of structural and functional brain changes. Metabolic and inflammatory biomarkers offer additional biological context. Alzheimer's disease represents the largest application because therapeutic innovation increasingly depends on biological confirmation of disease status. Parkinson's disease, ALS, Huntington's disease, and multiple system atrophy represent significant and growing application areas. Blood represents the fastest-growing sample type because healthcare providers seek less invasive diagnostic solutions. Cerebrospinal fluid remains important for specific applications where higher sensitivity is required. Pharmaceutical and biotechnology companies represent the leading end-user segment, with diagnostic laboratories and academic research institutes expanding biomarker utilization. The integration of AI is becoming increasingly important because biomarker research generates large and complex datasets. Industry participants are incorporating machine learning technologies to improve diagnostic accuracy and predictive performance.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and pharmaceutical companies alongside specialized biomarker, neurology, and analytical technology providers. Roche maintains a strategically distinct position because it combines pharmaceutical expertise with one of the most comprehensive diagnostics portfolios in the healthcare industry, expanding biomarker solutions designed to support diagnosis, patient stratification, and treatment monitoring within neurology care pathways. Fujirebio occupies a leading position because the company has established extensive expertise in neurodegenerative biomarker development, particularly within Alzheimer's disease diagnostics, expanding assay development and validation efforts to improve clinical implementation and accessibility. Quanterix differentiates itself through ultra-sensitive biomarker detection technologies capable of identifying low-abundance biological signals, expanding applications for its Simoa platform across Alzheimer's disease, Parkinson's disease, ALS, and related neurological disorders. Bio-Rad maintains strategic relevance because neurodegenerative biomarker development increasingly depends on advanced molecular analysis and quantitative measurement technologies, expanding molecular diagnostics and life science research capabilities to support biomarker discovery and validation initiatives. Thermo Fisher Scientific occupies an important position because the company provides a broad range of technologies supporting biomarker discovery, validation, and commercialization, expanding analytical technologies and laboratory solutions to address evolving requirements. QIAGEN maintains competitive strength through expertise in molecular diagnostics, sample preparation technologies, and biomarker development support, expanding technologies that support biomarker discovery, translational research, and clinical implementation activities. Siemens Healthineers differentiates itself through expertise in diagnostic imaging and laboratory diagnostics, both of which play important roles in neurodegenerative disease management. Companies are pursuing product portfolio expansion through innovation in blood-based biomarker assays, multi-omics platforms, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where aging populations are increasing the burden of neurodegenerative diseases.

Short Conclusion

The neurodegenerative biomarkers market is positioned for sustained growth driven by the convergence of early disease detection, disease-modifying therapies, and technological innovation. The transition from research-focused tools toward foundational components of neurological healthcare represents a fundamental shift in disease management. While challenges related to clinical validation, standardization, and reimbursement persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with neurodegenerative biomarkers evolving into a critical component of precision neurology, supporting early diagnosis, treatment selection, therapeutic monitoring, and drug development across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Neurodegenerative Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Neurodegenerative Disease Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Disease Burden and Unmet Clinical Needs Analysis
3.8 Epidemiology and Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Biomarker Testing Volume Analysis
3.11 Neurodegenerative Disease Diagnostic Pathway Analysis
3.12 Biomarker Role in Early Disease Detection
3.13 Biomarker Role in Therapeutic Monitoring

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
5.4 Stakeholder Ecosystem Analysis
5.5 Clinical Laboratory and Diagnostic Infrastructure Analysis

6. Innovation Landscape

6.1 Emerging Technologies in Neurodegenerative Biomarkers
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Neurodegenerative Biomarker Pipeline Analysis
6.5 Blood-Based Biomarker Development Trends
6.6 Multi-omics Biomarker Innovation
6.7 AI Integration in Biomarker Discovery and Interpretation
6.8 Digital Biomarker Development Trends
6.9 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
7.4 Biomarker Qualification Programs
7.5 Diagnostic Validation Requirements

8. Neurodegenerative Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Sample Type
8.4 Analysis by Disease Indication
8.5 Analysis by Clinical Application
8.6 Analysis by Testing Methodology
8.7 Analysis by End User
8.8 Analysis by Development Stage

9. Neurodegenerative Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Protein Biomarkers
- 9.1.2 Genetic Biomarkers
- 9.1.3 Imaging Biomarkers
- 9.1.4 Metabolic Biomarkers
- 9.1.5 Inflammatory Biomarkers
9.2 By Disease Indication
- 9.2.1 Alzheimer's Disease
- 9.2.2 Parkinson's Disease
- 9.2.3 Amyotrophic Lateral Sclerosis (ALS)
- 9.2.4 Huntington's Disease
- 9.2.5 Multiple System Atrophy
- 9.2.6 Other Neurodegenerative Disorders
9.3 By Technology Platform
- 9.3.1 Immunoassays
- 9.3.2 Molecular Diagnostics
- 9.3.3 Next-Generation Sequencing (NGS)
- 9.3.4 Mass Spectrometry
- 9.3.5 Neuroimaging Technologies
9.4 By Sample Type
- 9.4.1 Blood
- 9.4.2 Cerebrospinal Fluid (CSF)
- 9.4.3 Tissue Samples
- 9.4.4 Other Biological Samples
9.5 By End User
- 9.5.1 Hospitals and Clinics
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Academic and Research Institutes
- 9.5.4 Pharmaceutical and Biotechnology Companies
- 9.5.5 Contract Research Organizations (CROs)

10. Neurodegenerative Biomarkers Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Neurodegenerative Biomarkers Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Sweden
11.7 Japan
11.8 China
11.9 South Korea
11.10 Australia
11.11 India
11.12 Spain

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches
12.5 Competitive Benchmarking
12.6 Biomarker Development Partnership Analysis

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Fujirebio Holdings, Inc.
13.3 Quanterix Corporation
13.4 Bio-Rad Laboratories, Inc.
13.5 Thermo Fisher Scientific Inc.
13.6 QIAGEN N.V.
13.7 Danaher Corporation
13.8 Siemens Healthineers AG
13.9 Revvity, Inc.
13.10 C2N Diagnostics, LLC
13.11 Eisai Co., Ltd.
13.12 Biogen Inc.
13.13 Agilent Technologies, Inc.
13.14 Alamar Biosciences, Inc.
13.15 Sysmex Corporation